Abstract
After a delay of roughly 30 years, liposomes are becoming important as drug-targeting systems especially in anticancer therapy. Two liposomal anthracycline formulations are now available for cancer treatment and more are in preclinical tests or in clinical trials. This review summarizes the possibilities to improve the anticancer activity of certain drugs by entrapment in liposomes. We will briefly examine the problems and limitations of liposomal systems, from a pharmacokinetic as well as from a manufacturing viewpoint. Moreover, the anticancer properties of the two new liposomal anthracycline formulations will be discussed with regard to anticancer activity and side effects and compared with the properties of the respective free drugs. Copyright 2000 Harcourt Publishers Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
